DeutschNewstral
Article
Alaska Dispatch News on 2023-01-20 01:33
FDA declines to give accelerated approval to Lilly’s Alzheimer’s drug, firm says
Related news
- Eli Lilly to seek FDA approval for Alzheimer’s drug that firm says slows cognitive declineAlaska Dispatch News
FDA staff proposes narrow approval for Lilly’s Alzheimer’s drug - Thu, 06 Jun 2024 PSTsyndication.washingtonpost.com
What Is Donanemab? Eli Lilly’s Alzheimer’s Drug Gets Delayed Decision From FDAForbes
Eli Lilly applies for FDA approval on Alzheimer’s drugArkansas Online- FDA Panel Unanimously Recommends Eli Lilly’s Alzheimer’s DrugForbes
Breakthrough Alzheimer's drug earns accelerated FDA approvalNew York Post- MFDA chief tells reporters “transfer on” when pushing for approval of Biogen Alzheimer’smvtelegraph.com
Eli Lilly’s promising Alzheimer’s drug fails in clinical trialsFOX 8 News Cleveland
Pfizer breast cancer drug gets accelerated FDA approvalThe Salt Lake Tribune
FDA grants accelerated approval to Sarepta’s Duchenne drugbizjournals.com- Omeros seeks accelerated approval from FDA for new drugbizjournals.com
- Genentech pulls breast cancer drug after FDA questions accelerated approvalbizjournals.com
- MSanthera plummets 35% after FDA denies accelerated DMD drug approvalmarketwatch.com
First new Alzheimer’s drug in decades receives controversial FDA approvalnewatlas.com- FDA calls for federal investigation into approval of Alzheimer’s drugNew York Post
Alzheimer’s drug approval by FDA ‘rife with irregularities,’ probe findsLA Times
House investigation faults FDA, Biogen for Alzheimer’s drug approvalpost-gazette.com
Biogen Submits Promising Alzheimer’s Drug Aducanumab to FDA for Approvalobserver.com- BSigns Point to FDA Approval for Biogen’s Alzheimer’s Drugbarrons.com